Background
==========

Hyperinsulinaemic hypoglycaemia of infancy (HHI) is the most frequent cause of persistent neonatal hypoglycaemia and hypoglycaemia in infancy and is caused by dysregulation in insulin secretion. Molecular bases are known in 50--60% of patients. To date, eleven genes have been implicated, and the most frequent cause is mutations in the genes encoding K-ATP channel subunits. Heterozygous mutations in the *HNF4A* gene have been reported in cases of transient and persistent HHI, particularly in families with neonatal hypoglycaemia and adulthood diabetes ([@bib1]). The *HNF4A* gene encodes for the transcription factor hepatocyte nuclear 4a (HNF4a) that controls the expression of genes involved in glucose-stimulated insulin secretion; its mutations were first known to be the cause of monogenic diabetes type 1 (MODY 1).

Herein, we present a case of hyperinsulinaemic hypoglycaemia with a mutation in *HNF4A* and renal tubulopathy; this characteristic phenotype has been recently described and very few cases have been reported worldwide.

Case presentation
=================

A full-term large-for-gestational age boy (birth weight 4250 g + 2.7 [s.d.]{.smallcaps} and length 55 cm + 3.29 [s.d.]{.smallcaps}, head circumference 37 cm + 1.53 [s.d.]{.smallcaps}) developed hypoglycaemia on the first day of life. He was the second child of non-consanguineous Caucasian parents. High carbohydrate i.v. administration was required to maintain euglycaemia (up to 17 mg/kg/min). Laboratory results showed inappropriately low betahydroxybutyrate plasma levels (10.2 µmol/L), inappropriate insulin (6.1 IU/L) and C-peptide levels (2.7 ng/mL) and low cortisol levels (1.3 µg/dL and 5.2 µg/dL) in hypoglycaemia. The diagnosis of congenital hyperinsulinaemic hypoglycaemia was established. However, owing to low cortisol levels, hydrocortisone was started at 10 mg/m^2^/day without response. Function of other hypophyseal hormones was normal (thyroid hormones and testosterone levels were normal). Glucose in urine strips was detected on more than one occasion. Diazoxide was started at a dose of 8 mg/kg/day 24 h after initiation of hydrocortisone and intravenous glucose could be stopped, normalising total carbohydrate requirements. As the patient did not present hypoglycaemia after 6 h of fasting, he was discharged at 6 weeks of age on diazoxide at a dose of 6 mg/kg/day and with a nasogastric tube owing to feeding difficulties. Shortly after discharge, the diazoxide dose needed to be reduced owing to hyperglycaemia and was stopped at the age of three months since the glycaemia reached 300 mg/dL even with a dose lower than 3 mg/kg/day. Treatment was based only on frequent feeds, both oral and by nasogastric tube that was maintained until the age of 18 months.

At six months of age, the patient had failure to thrive and mild hepatomegaly (3 cm below the costal margin). Laboratory tests showed high serum transaminase levels (AST 80--90 IU/L, ALT 40--50 IU/L and GGT 60--100 IU/L). Laboratory tests for hepatotropic viruses and autoimmunity were negative. Liver biopsy was not performed as rises in liver enzymes were transient.

During follow-up, a progressive increase was observed in alkaline phosphatase (800--1384 IU/L), together with vitamin D deficiency (25OHD \<20 ng/mL) with low serum phosphate (3--3.2 mg/dL) but normal calcium (9.7 mg/dL) and magnesium (2.48 mg/dL) levels. Treatment with cholecalciferol was prescribed; however, the child gradually developed rickets with craniotabes, wrist widening, genu varum and motor impairment; findings on knee X-ray at 12 months of age were typical of rickets ([Fig. 1](#fig1){ref-type="fig"}). Further complementary tests at 18 months of age revealed non-gap metabolic acidosis (pH 7.27, bicarbonate 19.3) with acidified urine (pH 5.5) suggestive of proximal tubular acidosis, glycosuria with generalised aminoaciduria and tubular type proteinuria (β2 microglobulin \>4 mg/L), in addition to hypophosphatemia of renal origin (serum P 3.2 mg/dL and TRP 72%), hypercalciuria (UCa/Cr 0.5 mg/mg and UCa 3.7 mg/kg/day) and carnitine deficiency (total carnitine 29.3 µmol/L). 25OHD levels were normal at that time (30 ng/mL), but PTH was elevated (155 pg/mL). Fanconi-type proximal complex tubulopathy was diagnosed. By that time, he had lost 5.8 standard deviations in height and 4 standard deviations in weight since birth ([Fig. 2](#fig2){ref-type="fig"}). Supplementary oral treatment with phosphate, sodium bicarbonate, carnitine and 1-alpha-calcidiol was started immediately. Figure 1Growth chart over first 3 years of life. Figure 2Wrist and knee X-rays at 16 months of age.

Investigation
=============

Genetic testing for*KCNJ11* and *ABCC8* genes did not detect any mutation. Responsiveness to diazoxide and glucosuria pointed to *HNF4A* study, which revealed a heterozygous mutation in exon 2 of the *HNF4A* gene: p.Arg63Trp, c.187C \> T (reference sequence: NM_175914.4). Both parents tested negative for the mutation.

Treatment
=========

Diazoxide was started, and intravenous glucose could be stopped. On more than one occasion, the dose needed to be reduced owing to hyperglycaemia and had to be stopped by the age of three months. At six months of age, the patient was observed to have failure to thrive and mild hepatomegaly with slightly high serum transaminase levels. Tests for hepatotropic viruses and autoimmunity were negative. During follow-up, a progressive increase in alkaline phosphatase (800--1384 IU/L), vitamin D deficiency (25OHD: \<20 ng/mL), low serum phosphate (3--3.2 mg/dL), but normal calcium and magnesium levels were observed. The child gradually developed rickets despite treatment with cholecalciferol. Further complementary tests revealed proximal tubular acidosis, glycosuria with generalised aminoaciduria and tubular type proteinuria, in addition to hypophosphataemia, hypercalciuria and carnitine deficiency. Fanconi-type proximal complex tubulopathy was diagnosed, and supplementary oral treatment was initiated. After treatment was started, the patient gained weight and height and recovered from his skeletal abnormalities.

Outcome and follow-up
=====================

At 3 years and 9 months of age, the patient has currently no signs of active rickets and, despite persistent Fanconi syndrome, his metabolic control is satisfactory. Cognitive and motor development are age adequate; weight (14.3 kg, −1.4 [s.d.]{.smallcaps}) and height (95 cm, −2 [s.d.]{.smallcaps}) have normalised with growth catch-up ([@bib2]). He is now able to fast for eight hours; however, he remains on a 02:00 h intake that is being tapered. Minimal hepatomegaly and mildly increased transaminases (AST 98 IU/L, ALT 63 IU/L at the last control) remain, with transient peaks during episodes of viral upper respiratory tract infection or gastroenteritis.

Discussion
==========

The association between HHI and *HNF4A* mutations has been found in 0.5--2.4% of patients and was first reported by Pearson *et al*. ([@bib3]). That study also reported a link between those mutations and macrosomia in a significant percentage of carriers. Nevertheless, it was not until 2010 that the mutation in our patient (p.Arg63Trp, c.187C \> T also reported as p.Arg76Trp (p.R76W), c.226C\>T) was found to cause HHI, although the only patient reported to have it was not phenotypically described ([@bib4]). A second case with the same mutation was reported in 2012. That patient had the same features as our patient, including the liver disorder, together with a liver biopsy, which showed abundant cytoplasmic glycogen with mild portal inflammation and fibrosis ([@bib5]). In 2014, six more cases with our patient's mutation were reported, including the first previously published in 2010 and without a phenotypical description. These six patients had no liver disorder and, unlike the patient we report, also had 'atypical' Fanconi syndrome with hypercalciuria with relative hypocalcaemia, hypermagnesaemia, nephrocalcinosis and renal impairment. Two patients had developed diabetes mellitus at 12 and 20 years of age respectively ([@bib6]). Recently, Numakura *et al*. ([@bib7]) and Improda *et al*. ([@bib8]) each reported two additional cases, one of which had transient liver disease; the case described by Numukara presented hepatomegaly and raised serum transaminases at five months of age with normalisation at the age of three and that described by Improda had prolonged conjugated hyperbilirubinaemia which normalised over the first 3 months of life. Those authors suggested that transient liver enlargement could be a mutation-specific characteristic of p.R76W, taking into consideration that liver-specific *HNF4A*-knockout mice had hepatomegaly and that HNF4A regulates the expression of *SLC2A2*, a mutation which is a cause of Fanconi--Bickel syndrome ([@bib5], [@bib7]). However, not all the described patients with the R76W mutation presented liver impairment. Liver disease in our case has been permanent to date.

HNF-4α is known to regulate selected genes involved in insulin secretion; however, the precise molecular mechanisms by which *HNF4A* mutations cause insulin hypersecretion are not clearly understood ([@bib1]). There appears to be a relationship with PPARa levels. PPARa is a transcription factor that regulates fatty acid β-oxidation; lower levels of this factor might reduce β-oxidation of fatty acids, thereby increasing the availability of lipid signalling molecules that are necessary for insulin exocytosis. This would lead to abnormal insulin secretion during fasting ([@bib9]).

Our case provides further evidence of the role of the *HNF4A* gene in the renal proximal tubule (PT). Potential pathogenic mechanisms accounting for the generalised PT dysfunction and thus the occurrence of Fanconi syndrome in patients with *HNF4A* mutations are unknown; however, the mutation-specific effect and involvement of major regulatory genes have been postulated ([@bib6]). The*HNF4A* R76W mutation causes an atypical dominant Fanconi syndrome in addition to the beta cell phenotype. Other inherited diseases causing Fanconi syndrome and neonatal-onset hypoglycaemia, such as galactosaemia, tyrosinemia or mitochondrial diseases, were ruled out in our patient since his hypoglycaemia was due to hyperinsulinism. Further, Bickel--Fanconi syndrome is another Fanconi syndrome of hereditary origin with hypoglycaemia and liver impairment; however, symptoms usually appear later in infancy and hypoglycaemia is due to impaired liver release of glucose due to a GLUT2 deficiency. These facts also facilitated the differential diagnosis in our case.

The low cortisol levels found at diagnosis in our patient were noteworthy. This feature is relatively common among HHI patients and appears to be related to a lack of drive from the hypothalamic--pituitary axis, with inappropriately low plasma adrenocorticotropic hormone concentrations at the time of hypoglycaemia ([@bib10]). The mechanism of this low response is not clear; the presence of K-ATP channels in the ventromedial hypothalamus (involved in glucose sensing) suggests that these channels might be closed in HHI, thereby impairing the counter-regulatory response to hypoglycaemia. However, this blunted counter-regulatory response has also been described in patients with no mutations in *ABBC8/KCNJ11* genes. Hypoglycaemia-associated autonomic failure (HAAF) due to repeated hypoglycaemia has also been postulated. Further studies will be required to elucidate the counter-regulatory hormonal responses in patients with CHI.

The long-term follow-up of our patient should include glycaemic control in the search for the possible future onset of diabetes mellitus.

Our case adds to the understanding and subtleties of this rare and recently described mutation uniquely causing HHI and Fanconi syndrome. Our patient has permanent liver involvement and no atypical features in his FS, unlike the cases reported by Hamilton *et al*. ([@bib6]).

It is clear that subtle initial laboratory results in our patient might have yielded clues and an earlier diagnosis could have been made. We hope this report will help to raise awareness of the possibility of FS and liver disorder when faced with children with HHI.

Patient's perspective
=====================

Being parents, the most difficult thing for us was the uncertainty. It was at the Neonatal Care Unit where we were told about his first diagnosis: congenital hyperinsulinism. Our medical team told us that the causes and prognosis could be multiple. After a 6-week period at the Neonatal Unit, they let us take him home. Our endocrinologist, who has been accompanying us all these years, told us: 'please be patient'. Sometimes it has been difficult for us to keep calm, especially when he was 18 months old. We had the feeling that, beyond his first diagnosis, more and more new conditions were affecting him every now and then as he was growing up, such as proximal tubulopathy and raised transaminase levels. We could only 'relax' when the results of the genetic test arrived. The mutation of the gene *HNFA4* was finally providing a reason for the whole clinical picture. Our son is now leading a normal life thanks to his regular feeding. The most difficult thing for us is to make him take his medicines, but as he was born with all these disorders, he is fully aware of the benefits of doing so, despite being just a 4-year-old child.
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